Multiple sclerosis (MS) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) share similar symptoms but are two biologically distinct conditions, with different immune signatures, a study found. These findings help explain why treatments approved for MS generally show limited effectiveness for MOGAD, researchers said. “These findings support MOGAD as its…
treatment
Zydus Lifesciences received final approval from the U.S. Food and Drug Administration (FDA) to market a generic version of Vumerity (diroximel fumarate) for adults with relapsing forms of multiple sclerosis (MS) and other conditions. The drug will be sold as 231 mg delayed-release capsules, produced at Zydus’s…
Mesenchymal stem cell therapy shows promise for treating multiple sclerosis (MS), with improvements seen in disability, walking ability, vision, and auditory function, according to a recent review of published studies. The approach also seems to be well tolerated by people with MS, but more research is needed on…
Genentech‘s experimental oral therapy fenebrutinib has become the first Bruton’s tyrosine kinase (BTK) inhibitor to show positive Phase 3 results in both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS), the company announced. In what Genentech called “unprecedented results,” two late-stage trials testing…
A new wearable brain-mapping tool could dramatically change how doctors monitor people with multiple sclerosis (MS), making it easier to track disease progression and guide personalized care. Researchers showed the system, OPM-MEG, reliably detects abnormalities in the brain’s electrical activity in MS patients. The portable technology is a major…
Scientists at Case Western Reserve University (CWRU) in Ohio will use a new $2.5 million donation from the Thomas F. Peterson Jr. Charitable Trust to develop therapeutic strategies for multiple sclerosis (MS) and other neurological diseases. The commitment will support Paul Tesar, PhD, a CWRU professor and director of the…
Sativex (nabiximols) — a cannabis-based oral spray used to ease spasticity in certain people with multiple sclerosis (MS) — has been acquired by CNX Therapeutics, which will now market the therapy in Europe and other international regions. The therapy, previously developed by Jazz Pharmaceuticals, is approved as…
A robotic exoskeleton dubbed Atalante X, which allows people with severe mobility issues to stand upright for rehabilitation exercises, is now cleared by the U.S. Food and Drug Administration (FDA) for use by people with multiple sclerosis (MS) and a broader range of individuals with spinal cord injuries. Additionally,…
SUDO-550, an oral TYK2 inhibitor being developed by Sudo Biosciences, was found to be safe, well-tolerated, and to fully reach the brain in a first-in-human clinical trial involving healthy volunteers, according to clinical trial results. The Phase 1 clinical trial, which began dosing late last year, also showed…
Ultraviolet light therapy may help reduce inflammation and disease severity in people with multiple sclerosis (MS), according to data from a small Phase 1 clinical trial. Researchers used Octave’s MS Disease Activity (MSDA) scale — a clinically validated test for monitoring MS disease activity — and found the majority…
Metis Biotech‘s experimental oral therapy MTS-004 was safe and eased symptoms of pseudobulbar affect (PBA), a neurological condition marked by bouts of sudden, involuntary, and inappropriate laughter or crying, in people with multiple sclerosis (MS) and other neurological disorders. That’s according to data from a Phase 3 clinical…
Obexelimab, a therapy Zenas Biopharma is developing for a range of autoimmune diseases, almost completely prevented the formation of new inflammatory lesions in adults with relapsing forms of multiple sclerosis (MS) in the first three months of a clinical trial. That’s according to data from the first part…
Bionxt Solutions has launched the final animal study needed to prepare for human testing of BNT23001, its sublingual version of cladribine, in people with multiple sclerosis (MS). The 15-day dosing optimization study will compare Bionxt’s thin-film formulation with the approved tablet version of cladribine, sold as Mavenclad, in…
The first patient has been dosed in a Phase 1 clinical trial of Autolus Therapeutics‘ experimental CAR T-cell therapy, obecabtagene autoleucel (obe-cel), in people with progressive forms of multiple sclerosis (MS) who have failed to respond to existing treatments. Dosing took place at University College London Hospitals NHS…
Researchers have identified a protein that naturally slows myelin production — a finding that could lead to ways to repair myelin damage in multiple sclerosis (MS) and other neurological disorders. In mice, the protein (called Tfii-i) was found to limit the activity of genes that drive myelin formation. When…
I’d spent about five years trying to figure out what was wrong with me and then treat it when I got the phone call. During that time, I’d had three surgeries to repair old injuries and had been treated for chronic Q fever. I’d also been diagnosed with multiple…
Liberate Bio’s CAR-M cell therapy almost completely depleted B-cells in nonhuman primates, suggesting the approach may be used to treat B-cell diseases such as multiple sclerosis (MS) and some cancers. The therapy is designed to genetically engineer monocytes and macrophages, two types of immune cells, to target and…
As a law student in the Czech Republic, Jana Hlavacova specialized in international law and international relations, but a multiple sclerosis (MS) diagnosis led her to shift her professional focus. Applying her legal expertise to her work at the Czechia Ministry of Health, she now helps shape healthcare policy…
Abnormal brain cells, known as disease-associated radial glia or DARGs, may play a key role in driving chronic inflammation in people with progressive forms of multiple sclerosis (MS), a new study shows. Based on the finding, researchers are now working to better understand the biology of DARGs, with an…
The U.S. Food and Drug Administration (FDA) granted fast track designation to EG110A, EG 427‘s DNA-based therapy to treat neurogenic detrusor overactivity (NDO) — a bladder disorder that can arise from spinal cord injury or neurodegenerative conditions such as multiple sclerosis (MS). The FDA gives fast track status to experimental…
Seizures in people with multiple sclerosis (MS) may be driven by changes in levels of certain brain signaling molecules, implying that targeting these molecules may be a viable strategy to treat MS-related seizures, according to new research done in a mouse model. “If the same transporters and receptors are…
Kernal Biologics has been awarded up to $48 million in funding to accelerate the development of KR-402, a next-generation CAR T-cell therapy for multiple sclerosis (MS) and certain blood cancers. The funds come from the Advanced Research Projects Agency for Health’s (ARPA-H) EMBODY program, which aims to support the…
Researchers have identified two experimental medications that may promote myelin repair in people with multiple sclerosis (MS). The two compounds have shown promise in cell and animal models, and preclinical work is ongoing to bring them into clinical testing. The compounds were identified by academic researchers, but the program…
Quantum Biopharma says it is closer to initiating a Phase 2 clinical trial — one involving people living with multiple sclerosis (MS) — to test its experimental therapy Lucid-MS after receiving the final reports from two toxicology studies requested by the U.S Food and Drug Administration (FDA). The…
Zenas Biopharma has acquired global rights to develop the BTK inhibitor orelabrutinib to treat multiple sclerosis (MS) and other diseases. The deal with orelabrutinib’s developer, Innocare Pharma, includes rights to two other investigational therapies. Zenas will pay Innocare up to $100 million in cash and up to…
The world’s largest meeting on multiple sclerosis (MS) has wrapped up for the year, and the National Multiple Sclerosis Society (NMSS) played a central role in many of the advances highlighted there. Nearly 10,000 people attended the 41st Congress of the European Committee for Treatment and Research in Multiple…
Up to six years of continuous treatment with Briumvi (ublituximab) led to sustained reductions in relapse rates and a low rate of disability progression in people with relapsing forms of multiple sclerosis (MS), with no new safety concerns reported. That’s according to new long-term data from the…
Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium continues to show a significant effect on disability worsening in people with progressive forms of multiple sclerosis (MS), even in those without signs of active inflammation in the brain, a group with limited treatment options. That’s according to new data…
Increasing the dose of Ocrevus (ocrelizumab) by two- or threefold, depending on a person’s weight, did not provide additional benefit in slowing disability progression compared with the standard regimen in people with primary progressive multiple sclerosis (PPMS). That’s according to top-line data from the Phase 3b GAVOTTE…
Most people with relapsing forms of multiple sclerosis (MS) given Mavenclad (cladribine) did not experience confirmed disability progression for at least four years after starting on the approved therapy, according to new Phase 4 trial data. The results come from the CLARIFY-MS (NCT03369665) and MAGNIFY-MS (NCT03364036)…